Vraylar vs. Geodon
See how Vraylar and Geodon compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Vraylar is approved for four conditions, including bipolar depression and add-on treatment for major depressive disorder, while Geodon is approved mainly for schizophrenia and bipolar mania.
Geodon carries a stronger QT-prolongation warning and must be taken with a substantial meal, while Vraylar has no specific heart-rhythm warning and works with or without food.
Vraylar is a newer, brand-only drug with no generic version yet, while Geodon has been available as a lower-cost generic for years.
Vraylar vs. Geodon Drug Summary
Vraylar
Vraylar (cariprazine) is an atypical antipsychotic approved for schizophrenia in adults and teens 13 and older, and for all phases of bipolar I disorder, from manic episodes to depression. It is also approved as an add-on to antidepressants for major depressive disorder, and is taken as a once-daily capsule with or without food.
Geodon
Geodon (ziprasidone) is an atypical antipsychotic approved for schizophrenia and for acute manic or mixed episodes of bipolar disorder, either alone or combined with lithium or valproate for maintenance. It is taken as a twice-daily oral capsule with food, and is also available as a short-term injection for acute agitation.
Vraylar vs. Geodon Side Effects
Vraylar
Geodon
Vraylar vs. Geodon Dosage
Vraylar
Geodon
| STAGE | DOSE | WHEN |
| Starting dose | 1.5 mg once daily | Day 1 |
| Maximum dose | 6 mg once daily | If needed |
| Dose changes | 4 increases | Every day |
| STAGE | DOSE | WHEN |
| Starting dose | 20 mg twice daily | At the start |
| Maximum dose | 20-80 mg twice daily | If needed |
| Dose changes | 1 increase | As tolerated |
Vraylar
| STAGE | DOSE | WHEN |
| Starting dose | 1.5 mg once daily | Day 1 |
| Maximum dose | 6 mg once daily | If needed |
| Dose changes | 4 increases | Every day |
Geodon
| STAGE | DOSE | WHEN |
| Starting dose | 20 mg twice daily | At the start |
| Maximum dose | 20-80 mg twice daily | If needed |
| Dose changes | 1 increase | As tolerated |
Vraylar vs. Geodon Indications
Vraylar
Vraylar treats schizophrenia in adults and adolescents 13 and older, and covers every phase of bipolar I disorder, from manic and mixed episodes to depression. It is also FDA-approved as an add-on to antidepressants for major depressive disorder in adults, giving it one of the broadest approval profiles among newer antipsychotics.
Schizophrenia, ages 13 and up
Bipolar I manic or mixed episodes, ages 10+
Bipolar I depression, adults
Adjunctive treatment for major depressive disorder, adults
Geodon
Geodon treats schizophrenia in adults and manages acute manic or mixed episodes of bipolar I disorder, either on its own or alongside lithium or valproate for ongoing maintenance. A short-term injectable form is also approved for acute agitation in people with schizophrenia.
Schizophrenia, adults
Acute bipolar manic or mixed episodes (monotherapy)
Bipolar disorder maintenance, with lithium or valproate
Acute agitation in schizophrenia (injection only)
Vraylar vs. Geodon Pros and Cons
Vraylar
Vraylar carries the same class-wide boxed warning for mortality risk in elderly dementia patients, but avoids the added QT-prolongation warnings tied to Geodon. As a newer, brand-only drug, it costs more out-of-pocket with no generic option yet.
Pros
Approved for four separate conditions, including add-on treatment for MDD
Can be taken with or without food
No specific QT-prolongation warning, unlike Geodon
Approved for adolescents with schizophrenia and bipolar mania
Cons
No generic version available, so it stays a brand-only cost
Long half-life means side effects can take weeks to resolve after stopping
Higher akathisia rates in bipolar mania and MDD trials, up to 23%
No injectable option for acute agitation
Geodon
Geodon has been on the market since 2001 and is now available generically, giving it a longer track record and easier access. It requires closer heart-rhythm monitoring and must be taken with a substantial meal for proper absorption.
Pros
Available as a generic (ziprasidone), often cheaper than brand-only options
Over two decades of real-world clinical use since its 2001 approval
Available as a short-term injectable for acute agitation
Approved for bipolar maintenance combined with lithium or valproate
Cons
Carries specific warnings for QT-prolongation and torsade de pointes risk
Must be taken with a substantial meal for proper absorption
Not approved for adolescents or as an MDD add-on treatment
Risk of DRESS syndrome noted in labeling
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.